ABEO
Abeona Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
Negative Gross Margin
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ABEO
Abeona Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases
Biological Technology
--
12/19/2014
NASDAQ Stock Exchange
136
12-31
Common stock
6555 Carnegie Avenue, 4th Floor, Cleveland, OH 44103
--
Abeona Therapeutics, Inc., founded in Wyoming in 1974 under the name Chemex Corporation, was renamed Chemex Pharmaceuticals, Inc., in 1983. The company changed its registered address from Wyoming to Delaware on June 30, 1989. In 1996, the company merged with Access Pharmaceuticals, Inc., a private Texas company, and changed its name to Access Pharmaceuticals, Inc. The company is an emerging biopharmaceutical company dedicated to the development of a range of pharmaceutical product delivery technologies based primarily on the company's nano-polymer chemical technology and other drugs. The company currently has licenses to sell products in the United States, China and South Korea.
Earnings Call
Q1/2025
Estimate EPS-0.35
Actual EPS-0.24
Estimate Revenue--
Actual Revenue0
Abeona Therapeutics' Q1 2025: Unraveling Key Contradictions in Manufacturing, Patient Access, and Strategic Direction
May 20,2025 10:26
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
ABEO has released its 2025 Q3 earnings. EPS was reported at -0.1, versus the expected -0.34, beating expectations. The chart below visualizes how ABEO has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
